Ryan Kennedy, MD
Endocrinology, Diabetes & Metabolism · Bristol, TNNPI 1295053759
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Boehringer Ingelheim at 30.0% of the total. Reporting peaked in 2021 at $13,358 and has fallen 86.5% since, to $1,803 in 2025.
Across 787 payments — averaging $44.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- Medtronic$8K
- Lilly USA, LLC$7K
- Eli Lilly$2K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$622
- plus $5K from 33 others
Across 10 payments — averaging $7524.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$75K
What the payments were for
- Speaking & faculty fees$19,92057%
- Travel & lodging$2,1866%
- Food & beverage$12,93937%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 72 | $10,511 |
| Medtronic(2 entities) | 149 | $8,251 |
| Lilly USA, LLC | 97 | $6,921 |
| Eli Lilly | 24 | $1,982 |
| Novo Nordisk | 100 | $1,315 |
| Sanofi-aventis U.S. LLC | 38 | $622 |
| Dexcom, Inc. | 30 | $613 |
| Amgen(2 entities) | 33 | $573 |
| Bayer | 42 | $567 |
| AstraZeneca(2 entities) | 23 | $534 |
| Corcept Therapeutics | 21 | $387 |
| Abbott | 21 | $355 |
| Radius Health, Inc. | 12 | $285 |
| Insulet Corporation | 13 | $237 |
| Xeris Pharmaceuticals, Inc. | 10 | $209 |
| Novartis | 14 | $205 |
| Esperion Therapeutics, Inc. | 9 | $162 |
| Tandem Diabetes Care, Inc. | 6 | $152 |
| Merck | 10 | $134 |
| AbbVie | 8 | $121 |
| Pfizer | 5 | $115 |
| Clarus Therapeutics Inc. | 14 | $111 |
| BETA Bionics, Inc. | 4 | $95 |
| Ascendis Pharma Endocrinology Inc | 4 | $80 |
| Sequel Med Tech, LLC | 2 | $69 |
| Kyowa Kirin, Inc. | 4 | $61 |
| Averitas Pharma Inc. | 2 | $50 |
| Shire North American Group Inc | 3 | $44 |
| IBSA Pharma Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Johnson & Johnson | 3 | $41 |
| Cequr Corporation | 1 | $30 |
| Lifescan, Inc. | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $26 |
| Zealand Pharma US, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $14 |
| Recordati_rare_diseases_inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$15,125
- Minimed 770G System$2,250
- MINIMED 780G$1,500
- InPen$1,000
- Minimed 670G System$730
- Ozempic$121
- FARXIGA$101
- BYDUREON$101
How this compares
$35,071 in reported general payments places this provider in the 80th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 414 | $535,966 |
| OzempicSemaglutide | 207 | $334,599 |
| Tresiba Flextouch U-200Insulin Degludec | 149 | $230,180 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 58 | $127,714 |
| JardianceEmpagliflozin | 109 | $123,259 |
| TrulicityDulaglutide | 67 | $110,663 |
| Humulin R U-500Insulin Regular, Human | 60 | $93,695 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 69 | $91,871 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 70 | $79,160 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 57 | $66,938 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $61,584 |
| NovologInsulin Aspart | 119 | $58,986 |
| FarxigaDapagliflozin Propanediol | 53 | $57,515 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 38 | $47,091 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $45,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $6,921 | $697,202580 claims |
| Novo NordiskOzempic, Novolog, Rybelsus | $1,315 | $417,344342 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $10,511 | $246,663208 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $622 | $91,87169 claims |
| AstraZenecaFarxiga | $534 | $57,51553 claims |
| MerckJanuvia, Janumet | $134 | $37,00941 claims |
| Johnson & JohnsonInvokana | $41 | $28,43919 claims |
| BayerKerendia | $567 | $27,43126 claims |
| AbbVieSynthroid | $121 | $19,484232 claims |
| Antares Pharma, Inc.Xyosted | $14 | $11,59311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Bristol
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Pascal DauphinHendersonville$925K
- Shimon HararyMemphis$735K
- Lisa MyersGermantown$609K
- Amit VoraKnoxville$579K
- Terri JerkinsNashville$567K
- Samuel Dagogo-JackMemphis$407K
- Michael CarlsonNashville$381K
- David EscalanteJellico$326K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.